Combination of spironolactone and DPP-4 inhibitors for treatment of SARS-CoV-2 infection: a literature review
- 16 May 2024
- journal article
- review article
- Published by Springer Nature in Archives of Virology
- Vol. 169 (6) , 1-8
Abstract
Coronavirus disease 2019 (COVID-19) is still causing hospitalization and death, and vaccination appears to become less effective with each emerging variant. Spike, non-spike, and other possible unrecognized mutations have reduced the efficacy of recommended therapeutic approaches, including monoclonal antibodies, plasma transfusion, and antivirals. SARS-CoV-2 binds to angiotensin-converting enzyme 2 (ACE2) and probably dipeptidyl peptidase 4 (DPP-4) to initiate the process of endocytosis by employing host proteases such as transmembrane serine protease-2 (TMPRSS-2) and ADAM metallopeptidase domain 17 (ADAM17). Spironolactone reduces the amount of soluble ACE2 and antagonizes TMPRSS-2 and ADAM17. DPP-4 inhibitors play immunomodulatory roles and may block viral entry. The efficacy of treatment with a combination of spironolactone and DPP-4 inhibitors does not appear to be affected by viral mutations. Therefore, the combination of spironolactone and DPP-4 inhibitors might improve the clinical outcome for COVID-19 patients by decreasing the efficiency of SARS-CoV-2 entry into cells and providing better anti-inflammatory, antiproliferative, and antifibrotic effects than those achieved using current therapeutic approaches such as antivirals and monoclonal antibodies.Keywords
This publication has 82 references indexed in Scilit:
- Mineralocorticoid receptor-antagonism prevents COVID-19-dependent glycocalyx damagePflügers Archiv - European Journal of Physiology, 2022
- Relapses of idiopathic inflammatory myopathies after vaccination against COVID-19: a real-life multicenter Italian studyInternal and Emergency Medicine, 2022
- Predicting mortality in hospitalized COVID-19 patientsInternal and Emergency Medicine, 2022
- Antibody therapies for treatment of non-severe COVID-19Internal and Emergency Medicine, 2022
- Hotspots for SARS‐CoV‐2 Omicron variant spread: Lessons from New York CityJournal of Medical Virology, 2022
- An idiotypic network dysregulation could be related to the pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT) following vaccination with vaccines expressing Spike protein of SARS CoV2Internal and Emergency Medicine, 2022
- Emerging evidence for non-pharmacologic interventions in reducing the burden of respiratory illnessesInternal and Emergency Medicine, 2022
- Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19JAMA, 2020
- Spironolactone alleviates diabetic nephropathy through promoting autophagy in podocytesInternational Urology and Nephrology, 2019
- Characterization of Angiotensin Converting Enzyme-2 (ACE2) in Human UrineInternational Journal of Peptide Research and Therapeutics, 2006